Prescient Therapeutics begins recruiting for expanded trial of PTX-100 in blood cancer
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in...
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in...
Cancer results from the mutation of normal cells to tumour cells because of interaction between...
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech...
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy...
Cancer is one of the significant causes of death worldwide. As per the World Health...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.